Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells<i>via</i>Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways
ACR exhibited potent anticancer effects on <i>BRAF</i> <sup>V600E</sup>-mutant and vemurafenib-resistant melanoma cells by dual-targeting of MAPK and PI3K/AKT/mTOR pathways, indicating its potential as a novel therapeutic agent for melanoma treatment.
Authors
- Shin Usuki (ORCID: https://orcid.org/0000-0002-4363-6346)
- Y. Suzuki (ORCID: https://orcid.org/0000-0003-0799-1567)
- Yoshitomo Suhara (ORCID: https://orcid.org/0000-0002-4770-2910)
- Ichiro Yajima (ORCID: https://orcid.org/0000-0001-8705-9870)
- M Nishizawa
- Noritake Tanaka
Institutions
- Shibaura Institute of Technology (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-05-27
- DOI
- https://doi.org/10.21873/anticanres.17601
- Citations
- 4
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 3.74
Funders
- Japan Society for the Promotion of Science